TerumoMEX:4543N 91 Piotroski F-Score is 7 as of Jun. 25, 2026, which is at its 10-year median of 7.00. GuruFocus rates MEX:4543N with a GF Score™ of 91/100 and a GF Value™ of MXN373.91 (Significantly Undervalued). Among 805 Medical Devices & Instruments companies, Terumo ranks better than 92.42% on this metric.
Good Sign:
Piotroski F-Score is 7, indicates a very healthy situation.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Terumo has an F-score of 5 indicating the company's financial situation is typical for a stable company.
The historical rank and industry rank for Terumo's Piotroski F-Score or its related term are showing as below:
MEX:4543N'
s Piotroski F-Score Range Over the Past 10 Years
Min: 2 Med: 7 Max: 8
Current: 7
During the past 13 years, the highest Piotroski F-Score of Terumo was 8. The lowest was 2. And the median was 7.
Terumo (MEX:4543N) Piotroski F-Score Explanation
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Terumo Piotroski F-Score Related Terms
Terumo Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for Terumo's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:4543N vs ISRG, BDX, MDLN: Piotroski F-Score Comparison
For the Medical Instruments & Supplies subindustry, Terumo's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Terumo Piotroski F-Score vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Terumo's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Terumo's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
This Year (Mar26) TTM:
Last Year (Mar25) TTM:
Net Income was 5453.012 + 4348.877 + 3770.555 + 2996.346 = MXN16,569 Mil. Cash Flow from Operations was 4253.539 + 8603.467 + 4613.589 + 10104.299 = MXN27,575 Mil. Revenue was 33878.837 + 34112.769 + 34255.696 + 34128.361 = MXN136,376 Mil. Gross Profit was 18957.37 + 18236.775 + 17691.237 + 16934.517 = MXN71,820 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(250947.484 + 234503.873 + 235075.705 + 260640.288 + 262762.242) / 5 = MXN248785.9184 Mil. Total Assets at the begining of this year (Mar25) was MXN250,947 Mil. Long-Term Debt & Capital Lease Obligation was MXN11,354 Mil. Total Current Assets was MXN97,849 Mil. Total Current Liabilities was MXN61,449 Mil.
Net Income was 3933.147 + 4037.535 + 4802.331 + 2519.366 = MXN15,292 Mil.
Revenue was 29964.15 + 34502.308 + 35734.777 + 36225.295 = MXN136,427 Mil. Gross Profit was 15965.275 + 19207.939 + 19676.432 + 19013.558 = MXN73,863 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(202874.774 + 216897.671 + 241354.038 + 254587.678 + 250947.484) / 5 = MXN233332.329 Mil. Total Assets at the begining of last year (Mar24) was MXN202,875 Mil. Long-Term Debt & Capital Lease Obligation was MXN21,938 Mil. Total Current Assets was MXN99,300 Mil. Total Current Liabilities was MXN33,073 Mil.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Terumo's current Net Income (TTM) was 16,569.
==> Positive ==> Score 1.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Terumo's current ratio of this year was 1.59236294. Terumo's current ratio of last year was 3.00249416.
==> Last year's current ratio is higher ==> Score 0.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Terumo's number of shares in issue this year was 1475.391. Terumo's number of shares in issue last year was 1480.936.
==> There is smaller number of shares in issue this year, or the same. ==> Score 1.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Terumo's gross margin of this year was 0.52663281. Terumo's gross margin of last year was 0.54141379.
==> Last year's gross margin is higher ==> Score 0.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Terumo's asset turnover of this year was 0.54344304. Terumo's asset turnover of last year was 0.6724667.
==> Last year's asset turnover is higher ==> Score 0.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
1
+
1
+
0
+
1
+
1
+
0
+
1
+
0
+
0
=
5
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Terumo has an F-score of 5 indicating the company's financial situation is typical for a stable company.
Terumo (MEX:4543N) has a Piotroski F-Score of 7 as of Jun. 25, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Terumo and its competitors. This is near median its historical median of 7.00. Over the past decade, Terumo's Piotroski F-Score has ranged from 2.00 to 8.00. According to the industry distribution chart, Terumo ranks #61 out of 805 companies in the Medical Devices & Instruments industry, placing it in the top 7.6%.
Is Terumo's Piotroski F-Score too high?
Terumo's current Piotroski F-Score of 7 is near median its 10-year median of 7.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 8.00. The Medical Devices & Instruments industry median Piotroski F-Score is 5.00. Terumo's value of 7 is 40% above this industry median. Based on the distribution chart, Terumo ranks #61 out of 805 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Terumo has a GF Score™ of 91/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Terumo's Piotroski F-Score compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Terumo ranks #61 out of 805 companies for Piotroski F-Score. This places Terumo in the top 8% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. Terumo's value of 7 is 40% above this benchmark. Historically, Terumo's own Piotroski F-Score has ranged from 2.00 to 8.00 over the past decade. While the company's 10-year median is 7.00 vs. the industry median of 5.00, Terumo has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Medical Devices & Instruments company?
The median Piotroski F-Score among Medical Devices & Instruments companies is 5.00, based on 805 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Terumo's current Piotroski F-Score of 7 is 40% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Terumo and its competitors. For the Medical Devices & Instruments industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Terumo's current Piotroski F-Score is 7, which is near median its own 10-year median of 7.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Terumo stock overvalued right now?
Based on GuruFocus' analysis, Terumo (MEX:4543N) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN373.91, compared to a current price of MXN261.28 — trading 30.1% below its estimated fair value. The current Piotroski F-Score is 7, which is near median its 10-year median of 7.00 and 40% above the Medical Devices & Instruments industry median of 5.00. Terumo's overall GF Score™ is 91/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Terumo (MEX:4543N), the current Piotroski F-Score is 7 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Terumo (MEX:4543N) Overvalued in 2026?
Based on GuruFocus' analysis, Terumo stock appears to be undervalued.
The current stock price of MXN261.28 is trading 30.1% below its estimated GF Value™ of MXN373.91.
GuruFocus considers Terumo to be Significantly Undervalued.
Key valuation signals for MEX:4543N:
Piotroski F-Score: 7 (near median its 10-year median of 7.00)
GF Value™: MXN373.91 vs. price of MXN261.28 (30.1% below fair value)
Industry Position: 40% above the Medical Devices & Instruments median (#61 of 805)
No single metric tells the full story. See the MEX:4543N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Started as a clinical thermometer producer in Japan in 1921, Terumo is a comprehensive medical device player with a diversified global revenue. Its product portfolio includes prefilled syringes, insulin patch pumps, neurovascular or cardiac vascular interventional devices, and blood processing systems. As of 2025, the cardiac and vascular business is the largest segment, contributing over 60% of its total revenue. Geographically, North America is the largest region, with 38% of Terumo's revenue.
91GF Score
Get the complete analysis for MEX:4543N
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:4543N has been successfully added to your 
